EDIT - Editas Medicine, Inc.
IEX Last Trade
1.21
-0.010 -0.826%
Share volume: 40,660
Last Updated: Fri 27 Dec 2024 08:30:18 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$1.22
-0.01
-0.82%
Fundamental analysis
12%
Profitability
0%
Dept financing
8%
Liquidity
75%
Performance
10%
Performance
5 Days
-1.60%
1 Month
-44.09%
3 Months
-64.66%
6 Months
-74.05%
1 Year
-88.15%
2 Year
-85.27%
Key data
Stock price
$1.21
DAY RANGE
$1.18 - $1.32
52 WEEK RANGE
$1.25 - $11.58
52 WEEK CHANGE
-$87.86
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/11/2024
Company detail
CEO: Gilmore O’Neill
Region: US
Website: editasmedicine.com
Employees: 230
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: editasmedicine.com
Employees: 230
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Editas Medicine, Inc. focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness.
Recent news